A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) Versus Weekly Paclitaxel (NSC #673089) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The purpose of this study is to assess the effectiveness of the drugs paclitaxel versus cabozantinib in treating recurrent ovarian, primary peritoneal, or fallopian tube cancer and to determine the types and severity of side effects caused by treatment with these drugs. Chemotherapy is the standard treatment for cancer of the ovary, fallopian tube or peritoneum when it returns after initial treatment. A number of chemotherapy options exist for patients when their cancer grows despite treatment with the most effective chemotherapy (such as carboplatin or cisplatin). One of these agents is paclitaxel, which when administered weekly is associated with reduction in the growth of ovarian cancer in many women, and is associated with relatively mild side effects. However, newer classes of drugs versus weekly paclitaxel need to be studied in this disease. Cabozantinib is in a class of medications called tyrosine kinase inhibitors. Cabozantinib works by slowing or stopping the spread of cancer cells by blocking new blood vessel formation. New blood vessel formation is required for tumor growth. Currently, cabozantinib is experimental in the treatment of ovarian, fallopian tube, and primary peritoneal cancer and has not been approved by the FDA.
Back to Clinical Trials list